Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84 ng/mL after two cycles. (Front Immunol)
Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination
The CRC Digest